Toxicogenomics – A Drug Development Perspective - Genomic Biomarkers for Pharmaceutical Development - page 143

significant advantage of RNA-Seq is its enabling of the identification of novel biomarkers
(alternative splicing, mutation, isoform-specific expression, non-coding RNA, etc.). In addi-
tion, RNA-Seq will generate an order of magnitude more data per experiment. Employing
the required computational power and data analysis techniques will require corresponding
infrastructure designs incorporating massive storage and high internal bandwidth. With
improvement in technologies and analysis algorithms, microarray and RNA-Seq combined
holds great promise to reveal deeper insights into understanding fundamentals of gene
expression variations. While toxicogenomics is not expected to replace traditional toxicologi-
cal methods, the hope is that it will aid in both the earlier elimination of toxic compounds
from the drug pipeline and the discovery of new pathways of toxicity. If so, toxicogenomics
and traditional toxicology will perform synergistically in spawning and testing hypotheses,
and allow a complementary weight-of-evidence approach.
References
[1] FDA, < http: // www.fda.gov / downloads / AboutFDA / Transparency / Basics / UCM247465.pdf >; 2012 [accessed
08.01.13].
[2] Suresh S. Moving toward global science. Science 2011;333(6044):802.
[3] Blomme E, Semizarov D, Blomme E, editors. Genomics in drug discovery and development. Basic principles
of toxicology in drug discovery and development. New Jersey: John Wiley & Sons, Inc.; 2009.
[4] Gwathmey JK, Tsaioun K, Hajjar RJ. Cardionomics: a new integrative approach for screening cardiotoxicity
of drug candidates. Expert Opin Drug Metab Toxicol 2009;5(6):647-60.
[5] Redfern WS, et al. Safety pharmacology - a progressive approach. Fundam Clin Pharmacol 2002;16(3):161-73.
[6] Westhouse RA. Safety assessment considerations and strategies for targeted small molecule cancer therapeu-
tics in drug discovery. Toxicol Pathol 2010;38(1):165-8.
[7] Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;
3(8):711-15.
[8] Khromava A, et al. Manufacturers' postmarketing safety surveillance of inluenza vaccine exposure in preg-
nancy. Am J Obstet Gynecol 2012;207(3):S52-6.
[9] Sakai R, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis
factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res
2012;64(8):1125-34.
[10] Williams D. Monitoring medicines use: the role of the clinical pharmacologist. Br J Clin Pharmacol
2012;74(4):685-90.
[11] Wills Q, Mitchell C. Toxicogenomics in drug discovery and development - making an impact. Atla Altern
Lab Anim 2009;37:33-7.
[12] Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari CA. Microarrays and toxicology: the advent of toxicog-
enomics. Mol Carcinog 1999;24(3):153-9.
[13] NAC, Committee on Applications of Toxicogenomics Technologies to Predictive Toxicology, 'Applications of
Toxicogenomic Technologies to Predictive Toxicology and Risk Assessment'. 2007.
[14] Gallagher WM, Tweats D, Koenig J. Omic proiling for drug safety assessment: current trends and public-
private partnerships. Drug Discov Today 2009;14(7-8):337-42.
[15] Jacobs A. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new
drugs. Toxicol Lett 2009;186(1):32-5.
[16] Thomas RS, et al. Application of genomics to toxicology research. Environ Health Perspect 2002;110:919-23.
[17] Frueh FW, Huang SM, Lesko LJ. Regulatory acceptance of toxicogenomics data. Environ Health Perspect
2004;112(12):A663-4.
[18] Kondo C, et al. Predictive genomic biomarkers for drug-induced nephrotoxicity in mice. J Toxicol Sci
2012;37(4):723-37.
[19] Koufaris C, et al. Hepatic MicroRNA proiles offer predictive and mechanistic insights after exposure to gen-
otoxic and epigenetic hepatocarcinogens. Toxicol Sci 2012;128(2):532-43.